Trials in AF and acute coronary syndrome were stopped early for futility, but there’s hope for factor XIa inhibitors given the positive top-line results for asundexian for secondary stroke prevention.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/factor-xi-inhibitors-will-third-time-be-cv-charm-2026a10001tc?src=rss
Author :
Publish date : 2026-01-20 11:41:00
Copyright for syndicated content belongs to the linked Source.
